Alcobra’s ADHD drug meets goals, after excluding some data

Alcobra Ltd said its drug to treat adult attention deficit disorder met the main goals of a late-stage trial – but only after excluding data from four patients who reacted positively to a placebo. Alcobra's drug, Metadoxine, was tested in 300 patients as a treatment for attention deficit hyperactivity disorder, or ADHD – a common neurobiological condition in adults. The company said patients …

from Content Keyword RSS

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s